Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Funding Opportunity Title
National Coordinating Center for the George M. O’Brien Kidney National Resource Centers (U24 - Clinical Trial Not Allowed)
Activity Code

U24 Resource-Related Research Projects – Cooperative Agreements

Announcement Type
New
Related Notices

None

Funding Opportunity Announcement (FOA) Number
RFA-DK-22-008
Companion Funding Opportunity
RFA-DK-22-007 , U54 Specialized Center (Cooperative Agreements)
Number of Applications

Only one application per institution is allowed, as defined in Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)
93.847
Funding Opportunity Purpose

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for the George M. O’Brien Kidney Consortium -- National Coordination Center (NCC) to lead a nation-wide effort to advance kidney research. The O’Brien Kidney Consortium will consist of ~8 National Resource Centers (NRCs) tasked with developing and sharing specialized kidney resources tools, technologies, services, and expertise and one NCC to lead, manage, and harmonize all aspects of the Consortium. Specifically, the NCC will: (1) provide administrative support and coordination for the entire Consortium, (2) establish and curate a “one-stop-shop” sharing portal for the entire Consortium, (3) develop and implement a multipronged communication and education plan for researchers and students interested in conducting kidney research to maximize national outreach and impact, (4) ensure that patient viewpoints, priorities, and preferences inform all aspects of the Consortium, and (5) administer and manage a national Opportunity Pool program to address gaps and promote collaboration.

Key Dates

Posted Date
July 01, 2022
Open Date (Earliest Submission Date)
November 01, 2022
Letter of Intent Due Date(s)

November 1, 2022

Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS Scientific Merit Review Advisory Council Review Earliest Start Date
December 01, 2022 Not Applicable Not Applicable March 2023 May 2023 July 2023

All applications are due by 5:00 PM local time of applicant organization. 

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date
December 02, 2022
Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide,except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts ).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.

  3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.


  4. Table of Contents

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Background

For over 25 years, the George M. O’Brien Kidney Centers have played an essential role in advancing kidney research. To expand the breadth and impact of this important program, the NIDDK aims to improve coordination, enhance national outreach and sharing, and promote continuous innovation by establishing the "O’Brien Kidney “Consortium”. This Consortium will combine innovative National Resource Centers (NRCs) tasked with developing and sharing specialized kidney resources, tools, technologies, services, and expertise and a National Coordinating Center (NCC) to lead, manage, and harmonize all aspects of the Consortium.

Research Objectives and Scope

The NCC will lead, coordinate, manage, and harmonize all aspects of the work conducted by the Consortium to advance kidney research. The NCC will support the NRCs in their efforts to nationally share specialized resources including tools, technologies, services, and expertise beyond those typically available in an individual lab or institutional core. Specifically, the NCC will:

  1. Provide administrative support and coordination for the entire Consortium by planning, organizing, and supporting meetings, education, and outreach activities to meet Consortium objectives. .
  2. Ensure that the Consortium activities are inclusive of investigators from a broad range of scientific disciplines and expertise.
  3. Promotethe inclusion of investigators and fellows from diverse backgrounds. See the Notice of NIH's Interest in Diversity (NOT-OD-20-031).
  4. Establish and curate a central portal to ensure that all NRC resources are shared broadly with the national kidney research community and are readily accessible to anyone pursuing kidney research.
  5. Develop a multifaceted communication and education plan designed to maximize national outreach and impact, including information about all available resources and efforts to expand the pool of investigators pursuing kidney research.
  6. Give voice to people with kidney diseases by identifying and recruiting patient representatives and ensuring that their viewpoints, priorities, and preferences are incorporated in all aspects of the Consortium.
  7. Develop and administer a national Opportunity Pool program that addresses scientific and technological gaps and promotes new collaborations, with an emphasis on early-stage investigators and people new to kidney research.
     

Expected outcomes from the project period will be:

  • Provide valuable administrative support, coordination, and project management to the entire Consortium, thus contributing to a nation-wide effort to advance kidney research.
  • Development of a central portal that successfully shares unique resources, tools, technologies, services, and expertise that address fundamental challenges in kidney research.
  • Sharing of resources that effectively lower the barrier to entry for investigators that are new or from fields not traditionally involved in kidney research.
  • Attract and retain early-stage investigators and people new to kidney research.
  • Promotion of a scientifically diverse kidney workforce that includes investigators from a broad range of scientific disciplines and expertise.
  • Inclusion of investigators and fellows from diverse backgrounds (NOT-OD-20-031).
  • Implementation of a rigorous Consortium-wide quality management plan.
  • Active monitoring and reporting of QA/QC (Quality Assurance/Quality Control) for all NRC resources.
  • Informed patient perspectives in every aspect of the Consortium.
  • Active participation of NCC members in all Consortium-wide working groups and committees.
  • Lead highly collaborative Consortium-wide discussions that successfully identify emerging areas of science and anticipate the needs of the national kidney research community.
  • Implementation of a national Opportunity Pool program, supported by appropriate oversight and rigorous external peer review, that addresses scientific gaps and promotes collaboration.
     

Project Organization
 

The George O’Brien Kidney Consortium will consist of ~8 NRCs and one NCC. Whereas the NRCs will establish highly synergistic theme-based cores focused on generating shared resources, the NCC will facilitate the sharing of these resources with the wider kidney research community. The coordinated efforts of the NRCs and the NCC will be governed by a Steering Committee (SC) composed of contact Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) from each of the NRCs, the PD(s)/PI(s) of the NCC, and the NIDDK Project Scientist(s) (see under Section VI, Cooperative Terms and Conditions). Oversight will be provided by the NIDDK advisory council, which will act as an advisory to the NIDDK. Additional oversight will be provided by an external Consortium Management Board (CMB) that will be advisory to the NDDK Advisory Council and provide input into the overall progress of the Consortium. The CMB members will be appointed by the NIDDK and not by the grantees. Applicants should not propose CMB members. Consortium leadership and relevant investigators are expected to actively participate in all Consortium meetings, which will be arranged and coordinated by the NCC. Consortium members are expected to meet at least once a year for a face-to-face SC meeting in the Bethesda, MD area. All PDs/PIs are required to attend the first meeting of the Consortium, which is expected to take place in October 2023.


The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will host a pre-application webinar for those interested in learning more about Funding Opportunity Announcements (FOAs) RFA-DK-22-007, "George M. O'Brien Kidney National Resource Centers (U54 - Clinical Trial Not Allowed)" and RFA-DK-22-008, "George M. O'Brien Kidney National Coordination Center (U24 - Clinical Trial Not Allowed)" (details are forthcoming).

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed
New

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Clinical Trial?

Not Allowed: Only accepting applications that do not propose clinical trials.

Funds Available and Anticipated Number of Awards

NIDDK intends to commit $8,347,500 in FY 2023 to support two related funding opportunities, RFA-DK-22-008 and RFA-DK-22-007.

NIDDK expects to award 1 National Coordination Center (NCC) under this Funding Opportunity Announcement

Award Budget

The direct cost for this U24 award will be approximately $400,000 per year (excluding Opportunity Pool). The applicant(s) may ask for $600,000 or more per year for the Opportunity Pool. All Opportunity Pool costs are inclusive of any F&A for the NCC and the subawardees. As such, the NCC should not calculate F&A on the Opportunity Pool set aside.

The application budget for the NCC must reflect the actual needs of the proposed study.

Award Project Period

The maximum project period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Local Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession

Other

  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations
Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

Required Registrations

Applicant organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

  • System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
    • NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
    • Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. SAM registrations prior to fall 2021 were updated to include a UEI. For applications due on or after January 25, 2022, the UEI must be provided on the application forms (e.g., FORMS-G); the same UEI must be used for all registrations, as well as on the grant application.
  • eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their full SAM and Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. See, Reminder, Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, NOT-OD-22-019.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

While the PD(s)/PI(s) is not required to have expertise or background in kidney research, the PD(s)/PI(s) is required to have an established record of external funding and research accomplishment.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

Number of Applications

Only one application per institution is allowed.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Applications for the NRCs are invited through a separate, companion FOA (RFA-DK-22-007). While eligible applicant institutions may apply for both an NRC (RFA-DK-22-007) and an NCC (RFA-DK-22-008), individual PD(s)/PI(s) can only apply for either an NRC or an NCC. A named PD(s)/PI(s) for an NRC or NCC application may serve as an unpaid consultant on another NRC or NCC application for which he/she is not the PD/PI. Potential applicants are encouraged to contact the Program Official named in Section VII to discuss their applications.

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity

The letter of intent should be sent to:

John F. Connaughton, Ph.D.
Chief, Scientific Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-7797
Email: NIDDKletterofintent@mail.nih.gov

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Other Attachments: Statement of Willingness:

This statement should be provided as an PDF attachment and should be entitled “Willingness”. It is expected that the PD(s)/PI(s), as well as the applicant institution, have a commitment to serve the Consortium objectives as outlined in this FOA. Thus, applicant(s) should provide a statement counter signed by the Department Chair indicating their willingness to:

  • Cooperatively work with the Consortium and the NIDDK to share all NRC resources with the national research community and participate in all Consortium projects, working groups, activities, conference calls, meetings, or as needed during the award.
  • Actively seek input from the Consortium and NIDDK regarding resource or expertise needs that may arise during the performance of the project.
  • Cooperatively work with the Consortium to develop and execute Material Transfer Agreements (MTAs) to permit sharing of resources, including but not limited to tools, technologies, services, protocols, biological specimens, molecules, cells, animals, genetic material, de-identified patient samples, de-identified patient data, and images.

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed.

The contact PI is not required to have a background in Kidney research but should have an established record of external funding and research accomplishments.

R&R Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

The PD(s)/PI(s) will be required to declare a minimum effort of 2.4 person-months (20 percent) effort per year. Applications proposing Multiple PD(s)/PIs(s) must have a minimum combined PD/PI effort of 2.4 person months, and the role of each PD/PI should be clearly defined. Applications that do not propose this minimum effort will be withdrawn and will not be reviewed. The NCC may also include administrative assistant(s) and specialized support personnel (e.g. portal developer) and be clearly justified.

Applicant(s) should also include:

  • Consortium portal development and maintenance costs.
  • Support for all key personnel to travel to Bethesda MD area at least once per year throughout the project period (except in the first year, when two meetings should be planned), including the launch meeting anticipated for October 2023.
  • Travel, lodging and per diem for up to four patient partners and ten CMB members to attend the annual in-person meeting of the Consortium in Bethesda, MD.
  • A minimum of $20,000 from the NCC’s overall direct costs should be specifically devoted to supporting the educational enrichment of new and/or early-stage investigators and trainees.
  • Support for an Opportunity Pool of $600,000 or more per year (inclusive of all F&A costs) that will enable the conduct of research by new and early-stage investigators, the formation of new collaborations and partnerships, and the addition of new tools and techniques to the NRCs. The NCC should not calculate F&A on the Opportunity Pool set aside. Rather, the NCC should budget for costs associated with the administration of the Opportunity Pool (including key personnel). The NCC is also entitled to F&A costs on the first $25,000 of each subaward made from the Opportunity Pool. Please note that the F&A costs for the subaward institution are included in the total costs of each subaward.

R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

The objectives of the NCC are to: (1) provide administrative support and coordination for the entire Consortium, (2) establish and curate a “one-stop-shop” sharing portal for the entire Consortium, (3) develop and implement a multipronged communication and education plan for researchers including ESI/NI, investigators new to kidney research and students to maximize national outreach and impact, (4) ensure that patient viewpoints, priorities, and preferences inform all aspects of the Consortium, and (5) administer and manage a national Opportunity Pool program to address gaps and promote collaboration.

Research Strategy: As such, the Research Plan should outline strategies to:

  1. Provide leadership, administrative support, and project management to the entire Consortium by planning, organizing, and supporting meetings, education, and outreach activities to meet Consortium objectives. This should include:
    • An overview of the NCC, its objectives, and how they are aligned with the objectives of the Consortium.
    • An organizational chart of the NCC, identifying the proposed PD(s)/PI(s) and key personnel.
    • A description of relevant expertise, experience, and accomplishments of the proposed key personnel in the successful planning, direction, coordination, and management of a complex multi-institution Consortium. It is expected that diverse scientific expertise will be included at every level of NCC leadership. Inclusion of key personnel from groups underrepresented in science (NOT-OD-20-031) is always encouraged.
    • Strategies to maintain regular communication amongst Consortium members and facilitate Consortium working groups.
    • Plans to organize and support at least one annual, face-to-face meeting of the Consortium (except in the first year, when two such meetings should be planned).
    • Plans to negotiate, establish, execute, and manage third-party and consortium agreements (e.g., Material Transfer Agreements) between all NRCs and investigators and other external collaborators.
  2. Develop, deploy, and curate a central "one stop shop” portal to organize and facilitate sharing of all Consortium resources widely. Lead a Consortium-wide effort to develop metrics to evaluate their national distribution, usage, and impact.
  3. Establish and implement a multifaceted communication and education strategy to ensure that the NRC resources and all other aspects of the Consortium are widely publicized. This strategy should include:
    • Plans to use all appropriate modes of communication (including social media platforms) to ensure that researchers are aware of and encouraged to use Consortium resources.
    • Plans to execute and manage a national outreach program that will help enhance the diversity of the biomedical research workforce and assist investigators in training of techniques and procedures developed by the NRCs. Outreach may consist of a variety of activities and strategies like social media, seminar series, guest lectures, symposia, etc. Outreach to students, fellows and junior faculty is always encouraged.
    • Plans to develop and administer an educational enrichment program that will help mentor and train new (investigators who have not yet received independent NIH funding) and early-stage investigators, trainees and researchers who are new to kidney research. This program may involve travel support for these investigators, researchers and trainees to attend appropriate Consortium meetings or to the NRCs to learn new skills or methodologies.
  4. Strategies to actively engage the patient community. Propose innovative ways to identify and recruit patient representatives and ensure that their viewpoints, priorities, and preferences are incorporated in all aspects of the Consortium. Formulate specific plans for when and how patient representatives will be integrated into all Consortium activities.
  5. Plans to establish, manage, and promote a national Opportunity Pool program to address gaps and promote collaboration. Specifically, this program should:
    • Support the SC in a yearly assessment of infrastructure and resource needs. Work with the NRCs to identify technological and scientific gaps in kidney research and seek applicants who can develop resources that are not present in the Consortium, but if offered could benefit the national kidney research community.
    • Help develop and publicly announce requests for applications, advertise solicitations, and manage acceptance.
    • Seek prospectiveapplicants from diverse scientific and demographic backgrounds. Efforts to include under-represented minorities and participants from rural areas and under-resourced educational settings are always encouraged.
    • Describe specific guidelines for applicant eligibility and any additional review criteria that may help address anybias and select meritorious individuals. This program is expected to have an emphasis on early-stage investigators and people new to kidney research. As such, this program is not intended to support or supplement ongoing research of an established investigator or make awards primarily or predominantly to investigators and institutions already within the Consortium.
    • Establish an administrative process, with appropriate oversight and rigorous external peer review, to prioritize, fund, and track awards.
    • Establish procedures, formats, and timelines for integrating awardees and monitoring and reporting progress and outcomes (e.g., publications, subsequent awards). Include plans to integrate and harmonize the activities of supported projects with ongoing Consortium activities.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

The following modifications also apply:

The NIDDK intends the resource sharing plans for the George M. O’Brien Kidney Consortium (including the NRCs and NCC) to follow the policy and objectives stated in the original FOAs. Specifically, consistent with achieving the objectives of the Consortium, all resources, tools, technologies, services, expertise, protocols (including analytical methods), ontologies, biological samples and other research resources are to be shared immediately across the Consortium and made publicly available to the larger national research community as soon as QA/QC procedures have been completed, and in accordance with the policies developed by the SC. Any preliminary data included in this application must be made available to the Consortium upon award. Limited exceptions to the requirement for community dissemination may be identified by the SC. The NIDDK, will make all final decisions concerning resource sharing and data access policies, and all policies are subject to change by the NIH as deemed necessary to sustain program principles and priorities, or to ensure the highest standards for responsible research conduct within the project.

Recipients will comply with and implement the recommendations and decisions of the SC with respect to the sharing of resources developed by the Consortium investigators under the Consortium.

Recipients are expected to register resources supported by this FOA with the NIDDK Information Network (dkNET) at https://dknet.org/ and use Research Resource Identifiers (RRID) assigned through dkNET in any publication supported by this FOA.

Appendix:

Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

  • No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the unique entity identifier (UEI) provided on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

 

 

Use of Common Data Elements in NIH-funded Research

Many NIH ICs encourage the use of common data elements (CDEs) in basic, clinical, and applied research, patient registries, and other human subject research to facilitate broader and more effective use of data and advance research across studies. CDEs are data elements that have been identified and defined for use in multiple data sets across different studies. Use of CDEs can facilitate data sharing and standardization to improve data quality and enable data integration from multiple studies and sources, including electronic health records. NIH ICs have identified CDEs for many clinical domains (e.g., neurological disease), types of studies (e.g. genome-wide association studies (GWAS)), types of outcomes (e.g., patient-reported outcomes), and patient registries (e.g., the Global Rare Diseases Patient Registry and Data Repository). NIH has established a “Common Data Element (CDE) Resource Portal" (https://cde.nlm.nih.gov/home) to assist investigators in identifying NIH-supported CDEs when developing protocols, case report forms, and other instruments for data collection. The Portal provides guidance about and access to NIH-supported CDE initiatives and other tools and resources for the appropriate use of CDEs and data standards in NIH-funded research. Investigators are encouraged to consult the Portal and describe in their applications any use they will make of NIH-supported CDEs in their projects.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

For this particular FOA, note the following:

Reviewers are asked to especially consider the justification of the following:

  • Plans to share NRC resources nationally.
  • Plans to lead, manage and coordinate all Consortium activities to achieve Consortium objectives.
  • Plans to establish a comprehensive nationwide communication and education plan for investigators, researchers, and students, who wish to conduct kidney research.
  • Plans to administer and manage the national Opportunity Pool program to address the needs of the Consortium.
     

The methodologies and approaches proposed in the application may not be innovative, but should address the Consortium needs in achieving its goals and objectives of advancing kidney research.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

 

Does the proposed Center address the needs of the research Consortium that it will coordinate and administer? Is the scope of activities proposed for the Center appropriate to meet those needs? Will successful completion of the aims bring unique advantages or capabilities to the research Consortium?
 

Specific to this FOA: How appropriate is the proposed plan to provide effective administrative support and project management to the entire Consortium, and thus contribute to a nation-wide effort to advance kidney research? How appropriate are the sharing plans that involve developing central portal for investigators to request and access the Consortium resources?

 

Are the PD(s)/PI(s) and other personnel well suited to their roles in the Center? Do they have appropriate experience and training, and have they demonstrated experience and an ongoing record of accomplishments in managing collaborative research? Do the investigators demonstrate significant experience with coordinating collaborative basic or clinical research? If the Center is multi-PD/PI, do the investigators have complementary and integrated expertise and skills; are their leadership approach, governance, plans for conflict resolution, and organizational structure appropriate for the Center? Does the applicant have experience overseeing selection and management of subawards, if needed?

Specific to this FOA: How appropriate is the PD(s)/PI(s) experience in managing and coordinating a highly collaborative Consortium? How appropriate is the PD(s)/PI(s) track record of training investigators from diverse backgrounds

 

Does the application propose novel organizational concepts or management strategies in coordinating the research Consortium the Center will serve? Are the concepts, strategies, or instrumentation novel to one type of research program or applicable in a broad sense? Is a refinement, improvement, or new application of organizational concepts or management strategies proposed?

Specific to this FOA: How innovative are the proposed strategies to lead collaborative Consortium-wide discussions that successfully identify emerging areas of science and anticipate the needs of the national kidney research community? How appropriate are plans to identify and recruit patient representatives and ensure that their viewpoints, priorities, and preferences are incorporated in all aspects of the Consortium?

 

Are the overall strategy, operational plan, and organizational structure well-reasoned and appropriate to accomplish the goals of the research Consortium the Center will serve? Will the investigators promote strategies to ensure a robust and unbiased scientific approach across the Consortium, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the Consortium is in the early stages of operation, does the proposed strategy adequately establish feasibility and manage the risks associated with the activities of the Consortium? Are an appropriate plan for work-flow and a well-established timeline proposed? Have the investigators presented adequate plans to ensure consideration of relevant biological variables, such as sex, for studies of vertebrate animals or human subjects?

Specific to this FOA: How appropriate are the proposed plans to establish and implement a multifaceted communication and education strategy to maximize Consortium outreach and impact? How appropriate are the proposed plans for national Opportunity Pool program that include, organization of the overall process of solicitation, review, selection, and monitoring of these Projects, and how they address gaps and promote collaboration? How appropriate are the plans to actively monitor and report QA/QC for all resources?

 

Will the institutional environment in which the Center will operate contribute to the probability of success in facilitating the research Consortium it serves? Are the institutional support, equipment and other physical resources available to the investigators adequate for the Center proposed? Will the Center benefit from unique features of the institutional environment, infrastructure, or personnel? Are resources available within the scientific environment to support electronic information handling?

Specific to this FOA: How appropriate is the institutional record of leading, coordinating, managing, and harmonizing a highly collaborative Consortium? How appropriate is the institutional record of fostering an inclusive research environment and giving a voice to people with kidney disease?

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

   

For research that involves human subjects but does not involve one of the  categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the  categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

 

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

 

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

 

Not Applicable.

 

Not Applicable.

 

Not Applicable.

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

 

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Not Applicable

 

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

 

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).

 

For Consortia involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

 

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the NIDDK, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Diabetes and Digestive and Kidney Diseases Advisory Council. The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.

Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website. Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities, including of note, but not limited to:

If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.

Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex (including gender identity , sexual orientation, and pregnancy). This includes ensuring programs are accessible to persons with limited English proficiency and persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html

HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.

Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

The following special terms of the award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75, 2 CFR Part 200, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipient is anticipated during the performance of the activities. Under the cooperative agreement, the NIH's purpose is to support and stimulate the recipient's activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility reside with the recipient for the project as a whole, although specific tasks and activities may be shared among the recipient and the NIH as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

  • Ensuring adherence to the overall objectives of the Consortium.
  • Cooperating with the Consortium to share all Consortium resources with the national research community immediately upon validation.
  • Convening regular meetings to evaluate the progress of the Consortium.
  • Providing information and data to the CMB as requested by the NIDDK.
  • Serve as a voting member of the SC, and participate, along with critical staff, in SC meetings including face-to-face meetings as scheduled in the Bethesda MD area or at an alternate location approved by the NIDDK.
  • Apprise the Project Scientist (PS) and Program Officer (PO) of any potential impediments to execution of the objectives of the project.
  • Abiding by the governance of the Consortium and all program policies agreed upon by the SC and approved by the NIDDK.
  • Supporting the Opportunity Pool recipients (funded by the NCC).
  • Provide representation on all relevant committees and working groups established by the SC.
  • Participating in any additional meetings and activities of the Consortium to promote cross-program sharing of best practices.
  • Reporting annual and ad hoc progress reports to the NIDDK on all Consortium activities.
  • Participation in Consortium program evaluation activities, including ad hoc site visits by the NIDDK and other external evaluators.
  • Any third-party collaboration (including but not limited to interactions with organizations from industry, academia, and nonprofit institutions) should be governed by a research collaboration agreement (e.g., Clinical Trial Agreement, Research Collaborative Agreement, etc.) or any third-party contract mechanism(s) with terms that ensure the collaboration is conducted in accordance with the Cooperative Agreement, applicable NIH/NIDDK policies and procedures, and with written approval from NIDDK Program staff. Any relevant proposed third-party agreements related to the network studies between the grantee and the third-party will be provided to the NIDDK Program staff and NIDDK Technology Advancement Office for review, comment, and approval to assure compliance with NIH/NIDDK policies and network policies. Further, at the request of the NIDDK Program staff, any other network-relevant third-party agreements must be shared with NIDDK. Failure to comply with this term may prompt action in accordance with NIH Grants Policy Statement, Section 8.5 titled: “Special Award Conditions and Remedies for Noncompliance (Special Award Conditions and Enforcement Actions”, and Section 8.5.2, titled: “Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding Support”, noncompliance with the terms and conditions of award will be considered by the funding IC for future funding and support decisions and may result in termination of the award.”

Any involvement of a third-party (including but not limited to industry, academia, and nonprofit institutions) in the study and network activities that includes access to any network generated resources (i.e., data and biosamples), or study results that are not publicly available, or using the name of the network or study or the name of the NIH or NIDDK, is permitted only after written permission by the NIDDK Program staff who will consult with others at NIH and NIDDK Technology Advancement Office.

Resource Management and Sharing Plan:
 

The NIDDK-approved plan will become a term and condition of award, be routinely monitored during the award period, and compliance may factor into future funding decisions. By the end of the funding or proprietary period, a recipient or study group may not continue to use or share study-generated resources until those resources are available to the public via an NIDDK approved repository per the NIDDK approved sharing plan. The NIDDK has established a Central Repository to support the receipt, storage, and distribution of data, biosamples, and other resources generated in clinical studies funded by the NIH/NIDDK. When the NIDDK Central Repository is to be utilized, prior to enrolling participants, the PI or his/her designee will coordinate with the NIDDK Program and Central Repository staff to prepare for the eventual archiving and distribution of the study generated resources that are to be maintained in the Central Repository. All resources transferred to the Central Repository will be under the custodianship of the NIDDK. The study’s leadership will have proprietary control of and exclusive access to the resources per the NIDDK-approved sharing plan. Subsequently, these resources will be available to the wider scientific community in accordance with the NIH policy on Data Sharing (http://grants.nih.gov/grants/policy/data_sharing and, https://sharing.nih.gov/, and https://sharing.nih.gov/faq#/data-sharing.htm) as well as the NIDDK policy for resource sharing, https://www.niddk.nih.gov/-/media/Files/Research-Funding/Process/PublicversionNIDDKdatasharingpolicy2013July2013.pdf.

The NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

The NIDDK will designate program staff, including a Project Scientist (PS), a Program Officer (PO), and a Grants Management Specialist to provide normal program stewardship and administrative oversight of the cooperative agreement. The PO and Grants Management Specialist will be named in the Notice of Grant Award. The NIDDK will also invite an independent panel of external experts with relevant scientific expertise to form the CMB (Consortium Management Board). The CMB will meet to review the progress of the Consortium periodically and provide input to the NDDK Advisory Council.

The role of the PS in the cooperative agreement is to support and encourage the recipient's activities by substantial involvement as partners and facilitators in the process without assuming responsibilities that remain with the PD(s)/PI(s). The PS will:

  • Help guide the development of the Consortium by providing advice and coordination.
  • Facilitate Consortium interactions.
  • Facilitate partnership with the NIDDK and ensure that the directions taken by the Consortium are consistent with the NIDDK missions and objectives.
  • Assist in avoiding unnecessary duplication of effort across the Consortium and help coordinate collaborative research efforts that involve multiple sites.
  • Identify appropriate expertise for the CMB.
  • Attend and participate as a voting member in all SC meetings and serve as the liaison between the SC and CMB.
  • Participate in organizing the annual meeting of program stakeholders, specialized workshops, and webinars of the Consortium.
  • Review the scientific progress of the Consortium for compliance with operating policies developed by the SC, and may recommend to the NIDDK to withhold support, suspend, or terminate an award for lack of scientific progress or failure to adhere to policies established by the SC.

The Program Officer is responsible for the normal scientific and programmatic stewardship of the award. The PO will:

  • Interact with the PD(s)/PI(s) on a regular basis to monitor study progress. Monitoring may include regular communications with the PD(s)/PI(s) and staff, periodic site visits, observation of field data collection and management techniques, quality control, fiscal review, and other relevant matters; as well as attendance at SC and related meetings. The NIDDK retains, as an option, a periodic review of progress by researchers not involved with the study.
  • Select and form a CMB, comprised of the PS, PO, other NIH extramural staff with relevant scientific expertise or who manage research grant programs that relate scientifically to the objectives of the Consortium, and outside experts selected by the NIH.
  • Serve as Executive Secretary to the CMB or delegate these responsibilities.
  • Have the option to recommend, following evaluations of Consortium progress by the CMB (if applicable), the possible withholding, reduction, or reallocation, as appropriate, of support from any Consortium component that substantially fails to achieve its objectives according to the approved milestones or fails to comply with the Terms and Conditions of the award, at the appropriate times. The NIDDK will not permit further expenditures of NIDDK funds for a study after requesting closure except as specifically approved by the NIDDK.
  • Have the option to recommend, following evaluations of Consortium progress by the CMB (if applicable), an increase in support to engage in further research efforts within the original research scope, as appropriate, for any Consortium component exceeding its objectives according to the approved milestones and substantially improving state-of-the-art capabilities, at the appropriate times.
  • Participate in the SC meetings as an annex officio (non-voting) member.
  • Retain the option to recommend, with the advice of the PS, re-allocation of NIH support among recipients, as scientific objectives evolve.
  • Carry-out continuous review of all activities to ensure objectives are being met.
  • Consult the NIDDK Technology Advancement Office to facilitate a review, comment, and approval of any Consortium management agreements or research collaboration agreements with third-party collaborators to assure compliance with NIH/NIDDK policies and network policies.
  • Serve as the official NIH representative in all communication with the SC.

Additionally, an agency program official or IC program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.

Areas of Joint Responsibility include:

The PD(s)/PI(s) and NIH PS will be jointly responsible for participating in Consortium-wide activities and for establishing collaborations across the Consortium and with other related activities.

Steering Committee (SC)

The SC will be the primary governing body for all Consortium activities and . The voting membership of the SC will include: one PD/PI from each funded NRC and NCC and the NIH PS. The Chair(s) of the SC will be assigned by NIH Program Staff and may be chosen from outside the Consortium. A portion of the SC meetings may be open to the public. All aspects of the Consortium will be governed by the SC and overseen by the NIDDK and an NIDDK-appointed CMB.

If needed, other NIH staff members may also participate in SC meetings as nonvoting members. All SC decisions and recommendations that require voting will be based on a majority vote. The SC will meet bimonthly by videoconference and in-person at the annual SC meeting. The frequency of SC meetings can be adjusted on a Consortium need basis.

The SC will:

  • Identify scientific and administrative issues that can benefit by being addressed at the Consortium level .
  • Review progress of the Consortium toward meeting the overall Consortium objectives.
  • Ensure that the entire Consortium adheres to the guidelines developed by the SC and NIDDK.
  • Discuss and prioritize the projects from the National Opportunity Pool program, which will be managed by the NCC.
  • Ensure that the Consortium takes advantage of existing NIDDK and NIH resources and programs.
  • Establish, as necessary, subcommittees or working groups to ensure the progress and productivity of the Consortium.
  • Work with the CMB, which will evaluate the progress of the Consortium and advise the SC regarding the scientific directions of the program.
  • Foster collaboration, synergy, and sharing among the Consortium sites and investigators.
  • Oversee the planning of Consortium scientific activities, including dynamic adjustment as needs and opportunities arise.
  • Guide the development and documentation of the Consortium standards and guidelines.
  • Establish a robust administrative process, with appropriate oversight and rigorous external peer review, to prioritize, fund, and track all Opportunity Pool expenditures.
  • Evaluate progress in the Consortium sites and recommend adjustments in approaches if necessary, including implementation of new projects and changes to ongoing studies, and termination of projects.
  • Develop and approve the Consortium-wide intellectual property agreements consistent with the terms and conditions of the cooperative agreement awards, applicable regulations, and the policies and practices of the recipient institutions.

The NIDDK intends the resource sharing plans for the George M. O’Brien Kidney Consortium (including the NRCs and NCC) to follow the policy and objectives stated in the original FOAs. Specifically, consistent with achieving the objectives of the Consortium, all resources, tools, technologies, services, expertise, protocols (including analytical methods), ontologies, biological samples and other research resources are to be shared immediately across the Consortium and made publicly available to the larger national research community as soon as QA/QC procedures have been completed, and in accordance with the policies developed by the SC. Any preliminary data included in this application must be made available to the Consortium upon award. Limited exceptions to the requirement for community dissemination may be identified by the SC. The NIDDK, in consultation with the SC for this project, will make all final decisions concerning resource sharing and data access policies, and all policies are subject to change by the NIH as deemed necessary to sustain program principles and priorities, or to ensure the highest standards for responsible research conduct within the project.

Recipients will comply with and implement the recommendations and decisions of the SC with respect to the sharing of resources developed by the Consortium investigators under the Consortium.

Recipients are expected to register resources supported by this FOA with the NIDDK Information Network (dkNET) at https://dknet.org/ and use Research Resource Identifiers (RRID) assigned through dkNET in any publication supported by this FOA.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the SC chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual recipient. This special dispute resolution procedure does not alter the recipient's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50,Subpart D and DHHS regulation 45 CFR Part 16.

3. Reporting

When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement. NIH FOAs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over the threshold.  See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and 2 CFR Part 200.113 and Appendix XII to 45 CFR Part 75 and 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period.  The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS).  This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313).  As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available.  Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 and 2 CFR Part 200 – Award Term and Condition for Recipient Integrity and Performance Matters.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

Scientific/Research Contact(s)

Deepak Nihalani, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-6417
Email: deepak.nihalani@nih.gov


Ivonne Schulman, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-435-3350
ivonne.schulman@nih.gov

Peer Review Contact(s)

Ann A. Jerkins, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-2242
Email: ann.jerkins@nih.gov

Financial/Grants Management Contact(s)

Tommy Gunter
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-451-3447
Email: tommy.gunter@nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75 and 2 CFR Part 200.

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.